ArticlePreventive medicine2016
Younger age at initiation of the human papillomavirus (HPV) vaccination series is associated with higher rates of on-time completion.
Article in Preventive medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Human papillomavirus vaccination at age 9 or 10 years to increase coverage - a narrative review of the literature, United States 2014-2024.Human vaccines & immunotherapeutics · 2025Pooled it
- Trial
- Framing of national HPV vaccine recommendations and willingness to recommend at ages 9-10.Human vaccines & immunotherapeutics · 2023Trial
- Impact of Interventions to Improve Human Papillomavirus Vaccine Uptake on Other Vaccines Due: A Secondary Analysis of a Randomized Trial.Academic pediatricsTrial
- Is It Time to Reassess the Target Age of Human Papillomavirus Vaccination Globally?Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Electronic Health Record Alerts for Early Human Papillomavirus Vaccination.JAMA network open · 2026Article
- Using immunization registry data to explore initiation of HPV vaccination at ages 9 and 10.Human vaccines & immunotherapeutics · 2025Article
- Healthcare provider perspectives on HPV vaccinations at ages 9-10 in the United States.Human vaccines & immunotherapeutics · 2025Article
- Parental acceptance of HPV vaccinations at ages 9-10 in the United States.Human vaccines & immunotherapeutics · 2025Article
- Identifying HPV vaccination research priorities for the US.Human vaccines & immunotherapeutics · 2025Article
- Human papillomavirus vaccine administration opportunities at well visits in adolescents.BMC public health · 2025Article
- Article
- HPV vaccine-related articles shared on Facebook from 2019 to 2021: Did COVID make a difference?PEC innovation · 2024Article
- Approximate maximum likelihood estimation in cure models using aggregated data, with application to HPV vaccine completion.Statistics in medicine · 2024Article
- Article
- Who are vaccine champions and what implementation strategies do they use to improve adolescent HPV vaccination? Findings from a national survey of primary care professionals.Implementation science communications · 2024Article
- Understanding Barriers to Human Papillomavirus Vaccination among Parents of 9-10-Year-Old Adolescents: A Qualitative Analysis.Vaccines · 2024Article
- Current status and future directions for the development of human papillomavirus vaccines.Frontiers in immunology · 2024Review
- Assessing the long-term implications of age 9 initiation of HPV vaccination on series completion by age 13-15 in the US: projections from an age-structured vaccination model.Frontiers in pediatrics · 2024Article
- Optimizing timing of adolescent vaccines: Impact of initiating HPV vaccination before Tdap or meningococcal vaccination on timely completion of the HPV vaccine series.Human vaccines & immunotherapeutics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Vaccination rates for human papillomavirus (HPV) have remained disappointingly low. It is critical to identify methods to increase on-time vaccine series completion rates (before 13 or 15years). To determine whether younger age (9 to 10years of age) at HPV vaccine series initiation was associated with improved on-time completion rates compared to initiation at 11 to 12years, we examined the prevalence of on-time HPV vaccine series completion rates from August 2006 through December 2012 in a large, population-based cohort of children and adolescents (aged 9.5 to 27years) residing in Olmsted County, MN on December 31, 2012 (n=36,223). We compared age at vaccine initiation between individuals who successfully completed both 2 and 3 doses of the vaccination series on-time (before age 13.5 or 15.0years) using multivariate logistic regression. On-time completion of both 2 and 3 doses of the vaccine series by age 13.5 or 15.0years was significantly associated with initiation at 9 to 10years as compared to 11 to 12years after adjusting for sex, race, insurance status, frequent health care visits, and year of first vaccination (all p<.01). Interventions focused on beginning the vaccination series at 9 to 10years of age may result in higher rates of timely series completion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.